Floatz logo

Lmv-12

EGF-R Positive Non-Small Cell Lung Cancer

Hunan Province Tumor HospitalPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the EGF-R Positive Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Silevertinib
Black Diamond Therapeutics, Inc.
Phase 1/2CCC

Same molecule, other indications

Lmv-12 is also rated in:

RET fusion positive cancerDormant
CCC
Indicative ·
48 / 100
View asset →
MET AmplificationDormant
CCC
Indicative ·
48 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →